ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors & Media

  • Home
  • Investors & Media
  • News / Events
  • Press Releases
Investors & Media

Investors & Media

  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • Events
    • Email Alerts
  • Presentations
  • Company Information
  • Financial Information
  • Analyst Coverage
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

ContraFect Corporation Announces Third Quarter 2015 Financial and Operating Results

November 12, 2015

ContraFect Corporation to Announce Third Quarter 2015 Results on November 12, 2015

November 5, 2015

ContraFect to Present at 14th Annual BIO Investor Forum

October 13, 2015

ContraFect Appoints Clinical Development Leader, Cara Cassino, M.D., as Chief Medical Officer

September 16, 2015

ContraFect Corporation Announces Poster Presentation at the ICAAC/ICC 2015 Meeting for CF-301 for the Treatment of Staph Aureus Infections, Including MRSA

September 9, 2015

ContraFect Appoints Key Business Executives

September 8, 2015

FDA Grants Fast Track Designation to ContraFect's CF-301, the First of Its Lysins, Currently in Development for the Treatment of Staph Aureus Infections, Including MRSA

August 17, 2015

ContraFect Corporation Announces Second Quarter 2015 Financial and Operating Results

August 13, 2015

ContraFect Corporation Provides Update on CF-301 Phase 1 Trial

August 11, 2015

ContraFect Corporation to Announce Second Quarter 2015 Results on August 13, 2015

August 6, 2015

RSS
  • « Previous
  • 1...
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • Next »
© 2023 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter